{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:02:45Z","timestamp":1791925365644,"version":"4.3.4"},"reference-count":140,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Platinum-based chemotherapies, such as cisplatin, play a large role in cancer treatment. The development of resistance and treatment toxicity creates substantial barriers to disease control, yet. To enhance the therapeutic index of cisplatin-based chemotherapy, it is imperative to circumvent resistance and toxicity while optimizing tumor sensitization. One of the primary mechanisms by which cancer cells develop resistance to cisplatin is through upregulation of DNA repair pathways. In this review, we discuss the DNA damage response in the context of cisplatin-induced DNA damage. We describe the proteins involved in the pathways and their roles in resistance development. Common biomarkers for cisplatin resistance and their utilization to improve patient risk stratification and treatment personalization are addressed. Finally, we discuss some of the current treatments and future strategies to circumvent the development of cisplatin resistance.<\/jats:p>","DOI":"10.3390\/ijms22158199","type":"journal-article","created":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T12:59:24Z","timestamp":1627649964000},"page":"8199","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":133,"title":["Targeting DNA Damage Response and Repair to Enhance Therapeutic Index in Cisplatin-Based Cancer Treatment"],"prefix":"10.3390","volume":"22","author":[{"given":"Robert Csaba","family":"Kiss","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1502-6225","authenticated-orcid":false,"given":"Scarlett","family":"Acklin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/14740338.2011.543417","article-title":"Chemotherapy-induced peripheral neuropathies: From clinical relevance to preclinical evidence","volume":"10","author":"Balayssac","year":"2011","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"Galluzzi","year":"2012","journal-title":"Oncogene"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s004050050190","article-title":"Radiosensitization of advanced squamous cell carcinoma of the head and neck with cisplatin during concomitant radiation therapy","volume":"256","author":"Sharma","year":"1999","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/S12094-010-0474-z","article-title":"Chemotherapy-induced peripheral neuropathy: Clinical features, diagnosis, prevention and treatment strategies","volume":"12","author":"Sereno","year":"2010","journal-title":"Clin. Transl. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Damia, G., and Broggini, M. (2019). Platinum Resistance in Ovarian Cancer: Role of DNA Repair. Cancers, 11.","DOI":"10.3390\/cancers11010119"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/(SICI)1097-0215(19960611)66:6<779::AID-IJC12>3.0.CO;2-Z","article-title":"Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents","volume":"66","author":"Damia","year":"1996","journal-title":"Int. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.ejca.2007.05.003","article-title":"Targeting DNA repair as a promising approach in cancer therapy","volume":"43","author":"Damia","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejphar.2009.05.032","article-title":"Impaired DNA damage response\u2014An Achilles\u2019 heel sensitizing cancer to chemotherapy and radiotherapy","volume":"625","author":"Darzynkiewicz","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nrc3088","article-title":"DNA interstrand crosslink repair and cancer","volume":"11","author":"Deans","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12929-015-0185-4","article-title":"RNA interferences targeting the Fanconi anemia\/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells","volume":"22","author":"Dai","year":"2015","journal-title":"J. Biomed. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.bcp.2012.10.023","article-title":"Contributions of rat Ctr1 to the uptake and toxicity of copper and platinum anticancer drugs in dorsal root ganglion neurons","volume":"85","author":"Liu","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00424-015-1766-5","article-title":"VRAC: Molecular identification as LRRC8 heteromers with differential functions","volume":"468","author":"Jentsch","year":"2016","journal-title":"Pflugers Arch."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.15252\/embj.201592409","article-title":"Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs","volume":"34","author":"Lutter","year":"2015","journal-title":"EMBO J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3389\/fnins.2020.00287","article-title":"Chloride\u2014The Underrated Ion in Nociceptors","volume":"14","author":"Wilke","year":"2020","journal-title":"Front. Neurosci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/cts.12480","article-title":"Identification of OAT1\/OAT3 as Contributors to Cisplatin Toxicity","volume":"10","author":"Hu","year":"2017","journal-title":"Clin. Transl. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.phrs.2016.11.023","article-title":"Dual function of OCT2 and MATE1 in cisplatin induced nephrotoxicity","volume":"119","year":"2017","journal-title":"Pharmacol. Res."},{"key":"ref_17","first-page":"1459","article-title":"New Insight of OCT2 Regulation as Mediator for Cisplatin- Induced Nephrotoxicity","volume":"18","author":"Abdalla","year":"2017","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"11199","DOI":"10.1073\/pnas.1305321110","article-title":"Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2","volume":"110","author":"Sprowl","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"640392","DOI":"10.3389\/fonc.2021.640392","article-title":"Molecular Mechanisms of Chemotherapy Resistance in Head and Neck Cancers","volume":"11","author":"Kanno","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_20","first-page":"1663","article-title":"Cisplatin and platinum drugs at the molecular level. (Review)","volume":"10","author":"Boulikas","year":"2003","journal-title":"Oncol. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.dnarep.2013.04.020","article-title":"DNA damage response in peripheral nervous system: Coping with cancer therapy-induced DNA lesions","volume":"12","author":"Englander","year":"2013","journal-title":"DNA Repair"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.nbd.2004.09.013","article-title":"Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: A potential mechanism for neurotoxicity","volume":"18","author":"McDonald","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.nbd.2010.11.017","article-title":"Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons","volume":"41","author":"Podratz","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Tang","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrc.2015.4","article-title":"DNA repair, genome stability and cancer: A historical perspective","volume":"16","author":"Jeggo","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2015.2","article-title":"DNA damage and the balance between survival and death in cancer biology","volume":"16","author":"Roos","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.dnarep.2009.04.006","article-title":"Common mechanisms of PIKK regulation","volume":"8","author":"Lovejoy","year":"2009","journal-title":"DNA Repair"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1038\/emboj.2009.281","article-title":"Emerging common themes in regulation of PIKKs and PI3Ks","volume":"28","author":"Halazonetis","year":"2009","journal-title":"EMBO J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.trecan.2018.08.003","article-title":"Synthetic Lethality and Cancer\u2014Penetrance as the Major Barrier","volume":"4","author":"Ryan","year":"2018","journal-title":"Trends Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0962-8924(98)01383-X","article-title":"Molecular mechanisms of DNA double strand break repair","volume":"8","author":"Kanaar","year":"1998","journal-title":"Trends Cell Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/ars.2013.5668","article-title":"Ionizing radiation-induced DNA damage, response, and repair","volume":"21","author":"Santivasi","year":"2014","journal-title":"Antioxid. Redox Signal"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.biocel.2012.06.026","article-title":"BRCA1-dependent Chk1 phosphorylation triggers partial chromatin disassociation of phosphorylated Chk1 and facilitates S-phase cell cycle arrest","volume":"44","author":"Yarden","year":"2012","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/B978-0-12-380888-2.00003-0","article-title":"The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer","volume":"108","author":"Smith","year":"2010","journal-title":"Adv. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1349-7006.2010.01840.x","article-title":"Secondary mutations of BRCA1\/2 and drug resistance","volume":"102","author":"Dhillon","year":"2011","journal-title":"Cancer Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.otohns.2004.04.019","article-title":"Mutant Nbs1 enhances cisplatin-induced DNA damage and cytotoxicity in head and neck cancer","volume":"131","author":"Tran","year":"2004","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5237","DOI":"10.21873\/anticanres.11094","article-title":"High Expression of MRE11-RAD50-NBS1 Is Associated with Poor Prognosis and Chemoresistance in Gastric Cancer","volume":"36","author":"Altan","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1172\/JCI33816","article-title":"Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy","volume":"119","author":"Abuzeid","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/sj.bjc.6605980","article-title":"Molecular disruption of NBS1 with targeted gene delivery enhances chemosensitisation in head and neck cancer","volume":"103","author":"Araki","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1097\/00005537-200309000-00034","article-title":"Molecular disruption of the MRN(95) complex induces radiation sensitivity in head and neck cancer","volume":"113","author":"Li","year":"2003","journal-title":"Laryngoscope"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ijrobp.2006.09.019","article-title":"Radiosensitization of head\/neck squamous cell carcinoma by adenovirus-mediated expression of the Nbs1 protein","volume":"67","author":"Rhee","year":"2007","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41416-019-0697-x","article-title":"PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma","volume":"122","author":"Shen","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13046-019-1161-8","article-title":"Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK\/STAT3\/PD-L1 pathway","volume":"38","author":"Shen","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13058-019-1204-2","article-title":"Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51","volume":"21","author":"Lee","year":"2019","journal-title":"Breast Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000077461","article-title":"Mechanisms of DNA double strand break repair and chromosome aberration formation","volume":"104","author":"Iliakis","year":"2004","journal-title":"Cytogenet. Genome Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nrm1202","article-title":"Mechanism and regulation of human non-homologous DNA end-joining","volume":"4","author":"Lieber","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"a016600","DOI":"10.1101\/cshperspect.a016600","article-title":"Homologous recombination and human health: The roles of BRCA1, BRCA2, and associated proteins","volume":"7","author":"Prakash","year":"2015","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1101\/gad.1015202","article-title":"Autophosphorylation of the DNA-dependent protein kinase catalytic subunit is required for rejoining of DNA double-strand breaks","volume":"16","author":"Chan","year":"2002","journal-title":"Genes Dev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1269\/jrr.10168","article-title":"Differences in sensitivity to DNA-damaging Agents between XRCC4- and Artemis-deficient human cells","volume":"52","author":"Katsube","year":"2011","journal-title":"J. Radiat. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/35056049","article-title":"Chromosomal stability and the DNA double-stranded break connection","volume":"2","author":"Hoeijmakers","year":"2001","journal-title":"Nat. Rev. Genet."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1593\/neo.111032","article-title":"DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance","volume":"13","author":"Stronach","year":"2011","journal-title":"Neoplasia"},{"key":"ref_53","first-page":"9917","article-title":"53BP1 inhibits the migration and regulates the chemotherapy resistance of ovarian cancer cells","volume":"15","author":"Hong","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/ijc.23635","article-title":"Ku70 predicts response and primary tumor recurrence after therapy in locally advanced head and neck cancer","volume":"123","author":"Sancho","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Acklin, S., and Xia, F. (2021). The Role of Nucleotide Excision Repair in Cisplatin-Induced Peripheral Neuropathy: Mechanism, Prevention, and Treatment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22041975"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.dnarep.2015.09.003","article-title":"Nucleotide excision repair in humans","volume":"36","author":"Spivak","year":"2015","journal-title":"DNA Repair"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"329","DOI":"10.5306\/wjco.v8.i4.329","article-title":"Platinum-induced neurotoxicity: A review of possible mechanisms","volume":"8","author":"Kanat","year":"2017","journal-title":"World J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Duan, M., Ulibarri, J., Liu, K.J., and Mao, P. (2020). Role of Nucleotide Excision Repair in Cisplatin Resistance. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239248"},{"key":"ref_59","first-page":"6336","article-title":"Overexpression of xeroderma pigmentosum group C decreases the chemotherapeutic sensitivity of colorectal carcinoma cells to cisplatin","volume":"15","author":"Zhang","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3389\/fphar.2018.01197","article-title":"XPA, XPC, and XPD Modulate Sensitivity in Gastric Cisplatin Resistance Cancer Cells","volume":"9","author":"Dominguez","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_61","first-page":"1875","article-title":"XPC inhibition rescues cisplatin resistance via the Akt\/mTOR signaling pathway in A549\/DDP lung adenocarcinoma cells","volume":"41","author":"Teng","year":"2019","journal-title":"Oncol. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0960-9822(99)80118-3","article-title":"Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours","volume":"9","author":"Masters","year":"1999","journal-title":"Curr. Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1002\/ijc.24772","article-title":"Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in human gliomas","volume":"126","author":"Chen","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.dnarep.2010.03.010","article-title":"Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells","volume":"9","author":"Arora","year":"2010","journal-title":"DNA Repair"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/1476-4598-9-259","article-title":"Down-regulation of the nucleotide excision repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells","volume":"9","author":"Sabatino","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/em.22087","article-title":"Mechanisms of DNA damage, repair, and mutagenesis","volume":"58","author":"Chatterjee","year":"2017","journal-title":"Environ. Mol. Mutagen."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10495-019-01529-9","article-title":"Fibroblasts from patients with idiopathic pulmonary fibrosis are resistant to cisplatin-induced cell death via enhanced CK2-dependent XRCC1 activity","volume":"24","author":"Im","year":"2019","journal-title":"Apoptosis"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/cbf.3461","article-title":"Cytoplasmic APE1 promotes resistance response in osteosarcoma patients with cisplatin treatment","volume":"38","author":"Liu","year":"2020","journal-title":"Cell Biochem. Funct."},{"key":"ref_69","first-page":"2245","article-title":"Apurinic endonuclease 1 promotes the cisplatin resistance of lung cancer cells by inducing Parkin-mediated mitophagy","volume":"42","author":"Li","year":"2019","journal-title":"Oncol. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1158\/1541-7786.MCR-16-0227-T","article-title":"DNA Polymerase Beta Germline Variant Confers Cellular Response to Cisplatin Therapy","volume":"15","author":"Nemec","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.cell.2013.03.025","article-title":"The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutS\u03b1","volume":"153","author":"Li","year":"2013","journal-title":"Cell"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.dnarep.2014.03.027","article-title":"New insights and challenges in mismatch repair: Getting over the chromatin hurdle","volume":"19","author":"Li","year":"2014","journal-title":"DNA Repair"},{"key":"ref_73","first-page":"539","article-title":"Loss of DNA mismatch repair due to knockout of MSH2 or PMS2 results in resistance to cisplatin and carboplatin","volume":"11","author":"Fink","year":"1997","journal-title":"Int. J. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"12157","DOI":"10.1074\/jbc.M110.198804","article-title":"MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor","volume":"286","author":"Takahashi","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Li, Y., Zhang, S., Wang, Y., Peng, J., Fang, F., and Yang, X. (2018). MLH1 enhances the sensitivity of human endometrial carcinoma cells to cisplatin by activating the MLH1\/c-Abl apoptosis signaling pathway. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-5218-4"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Zhou, J., Wang, Y., Wang, Y., Yin, X., He, Y., Chen, L., Wang, W., Liu, T., and Di, W. (2014). FOXM1 modulates cisplatin sensitivity by regulating EXO1 in ovarian cancer. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0096989"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"666937","DOI":"10.3389\/fonc.2021.666937","article-title":"Integrated Analysis of Whole Genome and Epigenome Data Using Machine Learning Technology: Toward the Establishment of Precision Oncology","volume":"11","author":"Asada","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Hill, D.P., Harper, A., Malcolm, J., McAndrews, M.S., Mockus, S.M., Patterson, S.E., Reynolds, T., Baker, E.J., Bult, C.J., and Chesler, E.J. (2019). Cisplatin-resistant triple-negative breast cancer subtypes: Multiple mechanisms of resistance. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6278-9"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Koutsoukos, K., Andrikopoulou, A., Dedes, N., Zagouri, F., Bamias, A., and Dimopoulos, M.A. (2020). Clinical Perspectives of ERCC1 in Bladder Cancer. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228829"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"109304","DOI":"10.1016\/j.cbi.2020.109304","article-title":"Sclareol ameliorated ERCC1-mediated cisplatin resistance in A549 human lung adenocarcinoma cells and a murine xenograft tumor model by suppressing AKT-GSK3\u03b2-AP1\/Snail and JNK-AP1 pathways","volume":"332","author":"Pan","year":"2020","journal-title":"Chem. Biol. Interact."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Zhu, J., Hua, R.X., Jiang, J., Zhao, L.Q., Sun, X., Luan, J., Lang, Y., Sun, Y., Shang, K., and Peng, S. (2014). Association studies of ERCC1 polymorphisms with lung cancer susceptibility: A systematic review and meta-analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0097616"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1479-5876-9-31","article-title":"High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area","volume":"9","author":"Chiu","year":"2011","journal-title":"J. Transl. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13000-019-0885-2","article-title":"Low ERCC1 expression is a good predictive marker in lung adenocarcinoma patients receiving chemotherapy based on platinum in all TNM stages\u2014A single-center study","volume":"14","author":"Mladinov","year":"2019","journal-title":"Diagn. Pathol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Warta, R., Theile, D., Mogler, C., Herpel, E., Grabe, N., Lahrmann, B., Plinkert, P.K., Herold-Mende, C., Weiss, J., and Dyckhoff, G. (2014). Association of drug transporter expression with mortality and progression-free survival in stage IV head and neck squamous cell carcinoma. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0108908"},{"key":"ref_85","first-page":"5378567","article-title":"Overexpression of \u03b2-Catenin Induces Cisplatin Resistance in Oral Squamous Cell Carcinoma","volume":"2016","author":"Li","year":"2016","journal-title":"BioMed Res. Int."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.canlet.2004.11.049","article-title":"Nuclear expression of cIAP-1, an apoptosis inhibiting protein, predicts lymph node metastasis and poor patient prognosis in head and neck squamous cell carcinomas","volume":"224","author":"Tanimoto","year":"2005","journal-title":"Cancer Lett."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Yang, X.H., Feng, Z.E., Yan, M., Hanada, S., Zuo, H., Yang, C.Z., Han, Z.G., Guo, W., Chen, W.T., and Zhang, P. (2012). XIAP is a predictor of cisplatin-based chemotherapy response and prognosis for patients with advanced head and neck cancer. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0031601"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.3892\/mmr.2016.5473","article-title":"Expression and clinical significance of Apollon in esophageal squamous cell carcinoma","volume":"14","author":"Li","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.3892\/or.2017.5584","article-title":"Livin enhances chemoresistance in head and neck squamous cell carcinoma","volume":"37","author":"Yoon","year":"2017","journal-title":"Oncol. Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e2874","DOI":"10.1038\/cddis.2017.271","article-title":"BST2 confers cisplatin resistance via NF-\u03baB signaling in nasopharyngeal cancer","volume":"8","author":"Kuang","year":"2017","journal-title":"Cell Death Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1093\/annonc\/mdu367","article-title":"A 3\u2032-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"25","author":"Chung","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1111\/j.1742-4658.2010.07734.x","article-title":"BRCA1 16 years later: DNA damage-induced BRCA1 shuttling","volume":"277","author":"Yang","year":"2010","journal-title":"FEBS J."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2741\/4230","article-title":"The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers","volume":"19","author":"Paul","year":"2014","journal-title":"Front. Biosci."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Vatish, J., Wilkinson, B., Al-Ishaq, Z., Pujji, O., Isgar, B., Vidya, R., Matey, P., Sircar, T., and Mylvaganam, S. (2021). The use of genomic assays reduces rates of chemotherapy: A single-institution experience. Ir. J. Med. Sci.","DOI":"10.1007\/s11845-021-02650-y"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","article-title":"Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer","volume":"24","author":"Paik","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","article-title":"Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial","volume":"11","author":"Albain","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1200\/JCO.2009.24.4798","article-title":"Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study","volume":"28","author":"Dowsett","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/bcr1412","article-title":"A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients","volume":"8","author":"Habel","year":"2006","journal-title":"Breast Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1002\/cncr.25206","article-title":"Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population","volume":"116","author":"Toi","year":"2010","journal-title":"Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_102","first-page":"512-512","article-title":"Discovery and validation of a genomic signature to identify women with early-stage invasive breast cancer who may safely omit adjuvant radiotherapy after breast-conserving surgery","volume":"39","author":"Chang","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"596191","DOI":"10.3389\/fonc.2020.596191","article-title":"A Targeted Gene Panel for Circulating Tumor DNA Sequencing in Neuroblastoma","volume":"10","author":"Cimmino","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13073-019-0644-8","article-title":"Clinical utility of custom-designed NGS panel testing in pediatric tumors","volume":"11","author":"Surrey","year":"2019","journal-title":"Genome Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"616042","DOI":"10.3389\/fonc.2021.616042","article-title":"Personalization in Modern Radiation Oncology: Methods, Results and Pitfalls. Personalized Interventions and Breast Cancer","volume":"11","author":"Aristei","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.3389\/fonc.2019.01388","article-title":"Harnessing DNA Double-Strand Break Repair for Cancer Treatment","volume":"9","author":"Trenner","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbrc.2021.01.046","article-title":"Targeting RNF8 effectively reverses cisplatin and doxorubicin resistance in endometrial cancer","volume":"545","author":"Yang","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1158\/1541-7786.MCR-19-1211","article-title":"RNF8 Promotes Epithelial-Mesenchymal Transition in Lung Cancer Cells via Stabilization of Slug","volume":"18","author":"Kuang","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41467-017-02602-0","article-title":"Integrative genomic and transcriptomic analysis of leiomyosarcoma","volume":"9","author":"Chudasama","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccr.2013.12.007","article-title":"CARM1 methylates chromatin remodeling factor BAF155 to enhance tumor progression and metastasis","volume":"25","author":"Wang","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1073\/pnas.1114905109","article-title":"Histone H3R17me2a mark recruits human RNA polymerase-associated factor 1 complex to activate transcription","volume":"109","author":"Wu","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ccell.2019.12.015","article-title":"EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition","volume":"37","author":"Karakashev","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccell.2018.01.019","article-title":"BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency","volume":"33","author":"Sun","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"16303","DOI":"10.18632\/oncotarget.11422","article-title":"Sensitizing thermochemotherapy with a PARP1-inhibitor","volume":"8","author":"Oei","year":"2017","journal-title":"Oncotarget"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/annonc\/mdt384","article-title":"PARP Inhibitors for BRCA1\/2 mutation-associated and BRCA-like malignancies","volume":"25","author":"Lee","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"105292","DOI":"10.1016\/j.oraloncology.2021.105292","article-title":"PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data","volume":"117","author":"Moutafi","year":"2021","journal-title":"Oral. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"107391","DOI":"10.1016\/j.pharmthera.2019.07.002","article-title":"ATM in DNA repair in cancer","volume":"203","author":"Jin","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1535-7163.MCT-16-0378","article-title":"AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells","volume":"16","author":"Min","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1158\/0008-5472.CAN-17-0634","article-title":"ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage","volume":"77","author":"Perkhofer","year":"2017","journal-title":"Cancer Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1158\/0008-5472.CAN-16-3398","article-title":"ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma","volume":"77","author":"Schmitt","year":"2017","journal-title":"Cancer Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1182\/blood-2010-01-265769","article-title":"The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo","volume":"116","author":"Weston","year":"2010","journal-title":"Blood"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.chembiol.2013.12.014","article-title":"A small molecule screen identifies an inhibitor of DNA repair inducing the degradation of TFIIH and the chemosensitization of tumor cells to platinum","volume":"21","author":"Alekseev","year":"2014","journal-title":"Chem. Biol."},{"key":"ref_125","first-page":"a012609","article-title":"Nucleotide excision repair in eukaryotes","volume":"5","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/gtc.12674","article-title":"Spironolactone-induced XPB degradation depends on CDK7 kinase and SCF(FBXL18) E3 ligase","volume":"24","author":"Ueda","year":"2019","journal-title":"Genes Cells"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jid.2018.07.039","article-title":"Spironolactone Depletes the XPB Protein and Inhibits DNA Damage Responses in UVB-Irradiated Human Skin","volume":"139","author":"Kemp","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1021\/cb1000444","article-title":"Identification of novel small molecule inhibitors of the XPA protein using in silico based screening","volume":"5","author":"Neher","year":"2010","journal-title":"ACS Chem. Biol."},{"key":"ref_129","first-page":"4529","article-title":"Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: Association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins","volume":"59","author":"Jiang","year":"1999","journal-title":"Cancer Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"75104","DOI":"10.18632\/oncotarget.12072","article-title":"Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells","volume":"7","author":"Arora","year":"2016","journal-title":"Oncotarget"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41419-021-03804-7","article-title":"Small-molecule inhibition of APE1 induces apoptosis, pyroptosis, and necroptosis in non-small cell lung cancer","volume":"12","author":"Long","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_132","first-page":"485","article-title":"Identification of a novel potential antitumor activity of gossypol as an APE1\/Ref-1 inhibitor","volume":"8","author":"Qian","year":"2014","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1007\/s10637-020-00927-0","article-title":"A randomized, double-blind, placebo-controlled study of B-cell lymphoma 2 homology 3 mimetic gossypol combined with docetaxel and cisplatin for advanced non-small cell lung cancer with high expression of apurinic\/apyrimidinic endonuclease 1","volume":"38","author":"Wang","year":"2020","journal-title":"Investig. New Drugs"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Mesquita, K.A., Ali, R., Doherty, R., Toss, M.S., Miligy, I., Alblihy, A., Dorjsuren, D., Simeonov, A., Jadhav, A., and Wilson, D.M. (2021). FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers. Cancers, 13.","DOI":"10.3390\/cancers13081866"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"111026","DOI":"10.18632\/oncotarget.22195","article-title":"Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer","volume":"8","author":"Brill","year":"2017","journal-title":"Oncotarget"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1038\/s41388-020-1383-4","article-title":"Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer","volume":"39","author":"Nair","year":"2020","journal-title":"Oncogene"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ctrv.2016.03.002","article-title":"Targeting CDK4\/6 in patients with cancer","volume":"45","author":"Hamilton","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ccell.2020.01.007","article-title":"CDK4\/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma","volume":"37","author":"Xie","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3389\/fonc.2018.00608","article-title":"CDK 4\/6 Inhibitors as Single Agent in Advanced Solid Tumors","volume":"8","author":"Schettini","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41416-020-0891-x","article-title":"CDK4\/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms","volume":"123","author":"Skowron","year":"2020","journal-title":"Br. J. Cancer"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/15\/8199\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:37:21Z","timestamp":1760164641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/15\/8199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,30]]},"references-count":140,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["ijms22158199"],"URL":"https:\/\/doi.org\/10.3390\/ijms22158199","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,30]]}}}